Search Results
Your search for L matches 3307 pages
Showing 401 - 450Ruxolitinib for Patients With Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide
In a UK phase II trial (MAJIC-PV) reported in the Journal of Clinical Oncology, Harrison et al found that ruxolitinib produced a higher complete response rate vs best available therapy in patients with polycythemia vera intolerant of or resistant to hydroxycarbamide. Study Details In the...
Expert Point of View: Debra L. Richardson, MD and Joyce F. Liu, MD, MPH
Debra L. Richardson, MD, Associate Professor and Chief of the Section of Gynecologic Oncology, Oklahoma TSET Phase I Program, at the Stephenson Cancer Center, University of Oklahoma, Oklahoma City, discussed the emerging field of antibody-drug conjugates at a session on platinum-resistant ovarian...
Final SORAYA Analysis Supports Mirvetuximab Soravtansine in Ovarian Cancer
Treatment with the folate receptor alpha (FRα)-targeted antibody-drug conjugate mirvetuximab soravtansine-gynx benefited patients with FRα-high, platinum-resistant ovarian cancer, even after multiple lines of prior therapy, according to an updated analysis of the SORAYA trial presented at the...
Highlights of the SGO 2023 Annual Meeting on Women’s Cancer
The sun was out, and the weather was beautiful for the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer held in Tampa, Florida, in March 2023. Participants came from across the world for this second hybrid gathering since the COVID-19 pandemic to share ongoing advances in ...
Personalized Mind-Body Medicine in Integrative Oncology
Guest Editor’s Note: Substantial evidence supports the value of practices that focus on the interactions among the mind, body, and behavior for promoting health and well-being. In this article, Kavita K. Mishra, MD, MPH, summarizes a clinical model for personalized mind-body medicine in cancer care ...
Cancer Immunology and Immunotherapy: Principles and Practice
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, we begin a new series of articles on cancer immunology and immunotherapy, in which the authors discuss how immunotherapy has become a major pillar of...
Detection of Early Emphysema During Lung Cancer Screening: Opportunities to Optimize Health
In an article in Annals of the American Thoracic Society, James L. Mulshine, MD, of the Center for Healthy Aging, Department of Medicine, Rush University, and colleagues maintained that the high frequency of emphysema newly identified during low-dose computed tomography (CT) lung cancer screening...
Expert Point of View: Debra L. Richardson, MD and Joyce F. Liu, MD, MPH
Debra L. Richardson, MD, Associate Professor and Chief of the Section of Gynecologic Oncology, Oklahoma TSET Phase I Program, at the Stephenson Cancer Center, University of Oklahoma, Oklahoma City, discussed the emerging field of antibody-drug conjugates at a session on platinum-resistant ovarian...
Final SORAYA Analysis Supports Mirvetuximab Soravtansine in Ovarian Cancer
Treatment with the folate receptor alpha (FRα)-targeted antibody-drug conjugate mirvetuximab soravtansine-gynx benefited patients with FRα-high, platinum-resistant ovarian cancer, even after multiple lines of prior therapy, according to an updated analysis of the SORAYA trial presented at the...
The Role of Salpingectomy in Ovarian Cancer: Standard of Care or Targeted Therapy?
No one doubts the deadly nature of high-grade serous ovarian cancer. This histologic subtype is responsible for most ovarian cancer deaths, representing the eighth leading cause of cancer deaths in women worldwide and the fifth in the United States. Although there has been some progress in...
First-in-Patient Study of PSMA-Targeted Fluorescent Tracer for Intraoperative Imaging of PSMA-Positive Prostate Cancer
In a single-institution Dutch phase IIa feasibility trial reported in The Lancet Oncology, Stibbe et al evaluated the pharmacokinetics and safety of the prostate-specific membrane antigen (PSMA)-targeted fluorescent tracer OTL78 in patients undergoing robot-assisted radical prostatectomy for...
Newly Identified Risk Factors May Point to a Heightened Risk for Early-Onset Colorectal Cancer Among Younger Adult Patients
Researchers have identified four warning signs and symptoms that may indicate an elevated risk of early-onset colorectal cancer, according to a new study published by Fritz et al in the Journal of the National Cancer Institute. The findings may be key to helping physicians more effectively detect...
Clonal Hematopoiesis Risk Score for Myeloid Neoplasms in Patients With Myeloid Precursor Conditions
As reported in NEJM Evidence, Weeks et al identified a clonal hematopoiesis risk score for prediction of risk for myeloid neoplasms among individuals with clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS). As stated by the investigators, ...
Lindsay L. Peterson, MD, on Exercise and Cancer Outcomes
Lindsay L. Peterson, MD, of the Washington University, St. Louis, discusses the value of physical activity in improving cancer prognosis, especially for patients with breast or colon cancer. Aerobic exercises and resistance training are recommended during and after treatment. Exercise may help...
AUA and SUO Release New Guidelines for the Diagnosis and Treatment of Patients With Nonmetastatic Upper Tract Urothelial Carcinoma
The American Urological Association (AUA), in partnership with the Society of Urologic Oncology (SUO), have released recommendations for the diagnosis and management of patients with nonmetastatic upper tract urothelial carcinoma. The new clinical practice guidelines were published by Coleman et al ...
Social Drivers of Health: Grabbing the Steering Wheel
Study after study has demonstrated race-based differences in survival and other clinical outcomes for patients with cancer. But as health professionals, we are learning that these differences are less about a patient’s skin color and more about the legacy of racial inequality.1 This knowledge...
GLOW Trial: Zolbetuximab Plus Chemotherapy Sets New Treatment Standard in Gastric Cancer Subset
In the first-line setting, the monoclonal antibody zolbetuximab in combination with chemotherapy extended overall survival in patients with claudin-18.2 (CLDN18.2)-positive, HER2-negative, locally advanced or metastatic gastric adenocarcinoma. This regimen is now positioned as a new standard of...
Study Identifies Mutations That May Be Associated With Poor Outcomes in Patients With NSCLC Treated With KRAS G12C Inhibitors
Researchers have discovered that co-occurring mutations in three tumor-suppressor genes—KEAP1, SMARCA4, and CDKN2A—may be linked with poor clinical outcomes in patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC) who were treated with the KRAS G12C inhibitors adagrasib or sotorasib,...
Addressing Racial Disparities in Cancer Pain Management: A Potential Role for Music Therapy
Guest Editor’s Note: Despite its high prevalence, cancer pain remains undertreated. Racial disparities present further challenges to assessing and managing pain. Music therapy, a nonpharmacologic intervention, has been documented to be effective in controlling cancer pain. In this article, Kevin T. ...
Endoscopic Surveillance in Patients at Risk for Hereditary Diffuse Gastric Cancer
In a prospective cohort study reported in The Lancet Oncology, Asif et al found that endoscopic surveillance may be an alternative to prophylactic total gastrectomy in patients at risk for hereditary diffuse gastric cancer due to germline CDH1 pathogenic variants. Study Details In the study, 270...
Researchers Identify Potential Biomarkers of Response to Immunotherapy in Patients With Renal Cell Carcinoma
Researchers have revealed that the number of tumor-infiltrating lymphocytes, the state of necrosis, and mutations to the tumor-suppressor gene PBRM1 form a biomarker signature that may predict how patients with renal cell carcinoma will respond to immunotherapy, according to a novel study published ...
Yes, You Should Attend the 2023 ASCO Annual Meeting
The questions I am challenged to answer are twofold: (1) Should you attend the 2023 ASCO Annual Meeting? (2) If you attend, how is your time best spent? Most people agree scientific conferences are important venues for cancer researchers and clinicians to share and discuss research findings,...
Addressing Health Disparities in Oncology Care—Legally and Ethically
A health disparity is typically defined as involving a differential in health outcomes between some groups of patients and other groups, for example, between White and Black patients, in which some groups fare better than others. Health inequities are commonly defined as health differences that...
Mandi L. Pratt-Chapman, PhD, on Oncology Care in the LGBTQI+ Community: Best Practices for Addressing Health Needs
Mandi L. Pratt-Chapman, PhD, of the George Washington University Cancer Center, discusses the specific health-care needs for cancer screening, treatment, and survivorship among members of the LGBTQI+ community. Because clinical practices and research studies do not routinely collect sexual...
How Effectively Are You Helping Patients With Cancer at the End of Life?
“Providing hope when there is little to hope for is hard,” noted Hyman B. Muss, MD, Professor of Medicine and the Mary Jones Hudson Distinguished Professor of Geriatric Oncology at the University of North Carolina at Chapel Hill and the Lineberger Comprehensive Cancer Center. At the 2023 Miami...
Antibiotic Use and Survival Among Patients With Metastatic Pancreatic Cancer Receiving Specific Chemotherapy Regimens
In a retrospective cohort study reported in JAMA Network Open, Fulop et al found that perichemotherapy use of antibiotics was associated with improved survival in patients with metastatic pancreatic ductal adenocarcinoma receiving first-line gemcitabine-based chemotherapy, but not in those...
Poorer Survival in Stage III Colon Cancer With Greater Inflammation After Surgery and Prior to Adjuvant Therapy
In a study reported in JAMA Oncology, En Cheng, MD, PhD, of Kaiser Permanente Northern California, Jeffrey Meyerhardt, MD, MPH, FASCO, of Dana-Farber Cancer Institute, and colleagues found that higher levels of inflammatory biomarkers measured after surgery but before starting chemotherapy were ...
It Is Time to Close the Gap in Cancer Care
Cancer is a leading cause of death in every country worldwide.1 In 2020, almost 10 million people died of cancer, a number that is expected to rise to 16.3 million by 2040.2 In addition, cancer incidence continues to grow, driven by an aging and growing population and changes in the prevalence and...
FORMULA-509: Intensified Postoperative Regimen May Be of Benefit in Subset of High-Risk Prostate Cancer
The addition of abiraterone acetate and apalutamide to standard of care gonadotropin-releasing hormone (GnRH) agonist for 6 months and radiation therapy failed to improve progression-free survival and metastasis-free survival after prostatectomy compared to bicalutamide plus a GnRH agonist and...
Colorectal Cancer Rates Are Rising in Younger Adults, Shifting to More Advanced Disease Across All Ages
According to the American Cancer Society, colorectal cancer is the third most commonly diagnosed cancer and the third most common cause of cancer-related death in both men and women in the United States. However, it ranks second in cancer-related deaths overall and is the leading cause of cancer...
Cleveland Clinic Opens New Cancer Center in Abu Dhabi
Cleveland Clinic has announced the opening of a new state-of-the-art cancer facility, named the Fatima bint Mubarak Center, at Cleveland Clinic Abu Dhabi. “[This] marks the next step in fulfilling our mission to provide compassionate, complex care in the United Arab Emirates [UAE)]” said Tom...
GLOW Trial: Zolbetuximab Plus CAPOX Extends Survival in Gastric Cancer Subtype
First-line treatment with zolbetuximab in combination with capecitabine and oxaliplatin (CAPOX) extended overall survival in patients with claudin-18.2 (CLDN18.2)-positive/HER2-negative locally advanced or metastatic gastric adenocarcinoma, according to results of the GLOW trial reported by Xu et...
Patricia M. LoRusso, DO, PhD (hc), Elected 2023–2024 AACR President-Elect
The members of the American Association for Cancer Research (AACR) have elected Patricia M. LoRusso, DO, PhD (hc), as the President-Elect for the 2023 to 2024 term. Dr. LoRusso will become President-Elect on Monday, April 17, during the Annual Business Meeting of Members at the AACR Annual Meeting...
Understanding Fertility Issues in Young Patients With Breast Cancer
Young women with breast cancer have many concerns about their future fertility. How confident are you in discussing their chances of a future pregnancy, the effect of breast cancer treatment and fertility interventions on these offspring, and their risk of a compromised oncologic outcome after...
Detection of Emphysema During Lung Cancer Screening
In an article published in Annals of the American Thoracic Society, James L. Mulshine, MD, and colleagues maintained that the high frequency of emphysema newly identified during low-dose computed tomography (CT) lung cancer screening presents an important opportunity to engage individuals with such ...
New Research Highlights the Negative Impact of Continued Exclusion of Patients With African Ancestry From Research on Cancer Genomics
Researchers have revealed how the lack of genomic research for individuals with African ancestry—particularly those from the Sub-Saharan region—may be hampering efforts to reduce disparities for patients with prostate cancer, according to a new study published by Gheybi et al in JNCCN–Journal of...
Pilot Program Shows Diversity-Focused Clinical Trial Tools Are Useful at Cancer Research Sites
Cancer research sites demonstrated the utility of new resources designed to increase the diversity of participants in cancer clinical trials, although challenges remain, according to two studies published recently in JCO Oncology Practice.1,2 The studies examine the results from a collaborative...
Nicotinamide for Chemoprevention of Skin Cancer in Solid Organ Transplant Recipients
In an Australian phase III trial (ONTRANS) reported in The New England Journal of Medicine, Allen et al found that 1 year of treatment with nicotinamide (vitamin B3) vs placebo did not reduce the risk of keratinocyte cancers or actinic keratoses in immunosuppressed solid organ transplant...
Expert Point of View: David Wang, MD, PhD
David Wang, MD, PhD, Associate Professor of Internal Medicine at UT Southwestern Medical Center and VA North Texas Health Care System, was invited to discuss the CheckMate 649 and RATIONALE 305 studies. “CheckMate 649 was the first randomized controlled trial to demonstrate a significant survival...
Myelofibrosis-Related Anemia
This is Part 2 of Updates in Myeloproliferative Neoplasms, a three-part video roundtable series. In this video, Dr. Srden Verstovsek and Dr. Abdulraheem Yacoub discuss the management of patients with anemia as a presenting symptom of myelofibrosis. The patient is a 68-year-old woman who...
Regardless of Income, American Indian/Native American Women May Be Less Likely to Undergo Mammography Than White Women
Investigators found that American Indian/Native American women living in higher-income communities did not have a higher mammography uptake compared with American Indian/Native American women living in lower-income communities, according to a new study published by Christensen et al in the American ...
American Cancer Society Data Show Colorectal Cancer Rates Are Rising in Younger Adults and Shifting to More Advanced Disease in People of All Ages
According to the American Cancer Society, colorectal cancer is the third most commonly diagnosed cancer and the third most common cause of cancer-related death in both men and women in the United States. However, it ranks second in cancer-related deaths overall, and is the leading cause of death in ...
Prediction Models for Kidney Failure in Long-Term Survivors of Childhood Cancer
In a study reported in the Journal of Clinical Oncology, Wu et al developed models for predicting kidney failure among 5-year survivors of childhood cancer. Study Details In the study, predictive models were developed using data from 25,483 survivors from the Childhood Cancer Survivor Study (CCSS)...
New Study Demonstrates Inferior Vena Cava Filters May Be Safe and Effective Way to Prevent Venous Thromboembolism
Researchers have discovered that few adverse events may be associated with the use of inferior vena cava filters to help prevent deep vein thrombosis from developing into pulmonary embolisms, according to a new study jointly published by Johnson et al in the Journal of Vascular and Interventional...
Expert Point of View: Adam M. Brufsky, MD
Commenting on the study from Tata Memorial Centre for The ASCO Post, Adam M. Brufsky, MD, Professor of Medicine, Associate Chief of the Division of Hematology/Oncology and Co-Director of the Comprehensive Breast Cancer Center at the University of Pittsburgh School of Medicine, noted that the...
Have We Reached the Limits of Chemotherapy for Burkitt Lymphoma?
Burkitt lymphoma (BL) is a fascinating disease from which many groundbreaking medical and oncologic lessons have been learned. Since the Irish surgeon Denis P. Burkitt, MD, FRCS, FRS, first described rapidly enlarging jaw and facial tumors in Ugandan children in 1958,1 the study of BL has led to...
Paul L. Nguyen, MD, on Prostate Cancer: New Findings on Treatment With Salvage Radiotherapy, GnRH Agonist, Abiraterone, Prednisone, and Apalutamide
Paul L. Nguyen, MD, of Dana-Farber Cancer Institute and Harvard Medical School, discusses results from the FORMULA-509 study, which compared postoperative salvage radiotherapy and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide, after radical...
Intensified Drug Regimen Added to Standard of Care Improves Outcomes in Subset of Patients With High-Risk Prostate Cancer
In the phase III FORMULA-509 trial, the addition of abiraterone acetate/prednisone and apalutamide—compared with bicalutamide—to salvage radiation therapy plus 6 months of treatment with a gonadotropin-releasing hormone (GnRH) agonist failed to improve progression-free survival postprostatectomy in ...
Acupuncture for Chemotherapy-Induced Peripheral Neuropathy: Health-Related Quality-of-Life Outcomes From a Randomized Clinical Trial
Guest Editor’s Note: Chemotherapy-induced peripheral neuropathy is a common and potentially debilitating side effect of neurotoxic chemotherapy. It worsens the quality of life for many cancer survivors, with limited treatment options. In this installment of The ASCO Post’s Integrative Oncology...
Common Immune-Related Adverse Events: Spotlight on Gastrointestinal and Hepatic Toxicities
At the inaugural MD Anderson Clinical Education Symposium on Immunotherapy Organ Toxicity Management (IOTOX), a panel of experts discussed common immune-related adverse events associated with immune checkpoint inhibitor therapy, including gastrointestinal (GI), hepatic, dermatologic, pulmonary, and ...
